Lloyd A. Rowland net worth and biography

Lloyd Rowland Biography and Net Worth

General Counsel of CytomX Therapeutics

Lloyd Rowland, Jr. joined CytomX in May 2018 and currently serves as consulting general counsel. Mr. Rowland brings 25 years of biotechnology and pharmaceutical industry legal counsel and transactional experience to CytomX. Prior to CytomX, Mr. Rowland held the position of senior vice president, general counsel and chief compliance officer of Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Prior to this, Mr. Rowland held various roles at Amylin Pharmaceuticals throughout his twelve-year career, most recently as vice president and chief compliance officer and previously, as vice president, general counsel and secretary. During his time as general counsel at Amylin, he directed all corporate legal and compliance affairs for the company including the launch of two pharmaceutical products. Prior to joining Amylin, Mr. Rowland served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland received his B.S. degree in economics and political science from Southern Methodist University, and his J.D. from Emory University School of Law.

What is Lloyd A. Rowland's net worth?: The estimated net worth of Lloyd A. Rowland is at least $674.36 thousand as of March 18th, 2025. Rowland owns 120,594 shares of CytomX Therapeutics stock worth more than $674,362 as of February 24th. This net worth approximation does not reflect any other investments that Rowland may own. Learn More about Lloyd A. Rowland's net worth.
How do I contact Lloyd A. Rowland?: The corporate mailing address for Rowland and other CytomX Therapeutics executives is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. CytomX Therapeutics can also be reached via phone at (605) 515-3185 and via email at [email protected]. Learn More on Lloyd A. Rowland's contact information.
Has Lloyd A. Rowland been buying or selling shares of CytomX Therapeutics?: Lloyd A. Rowland has not been actively trading shares of CytomX Therapeutics over the course of the past ninety days. Most recently, Lloyd A. Rowland sold 10,203 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a transaction totalling $6,121.80. Following the completion of the sale, the general counsel now directly owns 120,594 shares of the company's stock, valued at $72,356.40. Learn More on Lloyd A. Rowland's trading history.
Who are CytomX Therapeutics' active insiders?: CytomX Therapeutics' insider roster includes Marcia Belvin (SVP), Sean McCarthy (CEO), Christopher Ogden (CFO), and Lloyd Rowland (General Counsel). Learn More on CytomX Therapeutics' active insiders.
Are insiders buying or selling shares of CytomX Therapeutics?: During the last twelve months, insiders at the biotechnology company sold shares 5 times. They sold a total of 79,947 shares worth more than $47,968.20. The most recent insider tranaction occured on March, 18th when CEO Sean A Mccarthy sold 37,656 shares worth more than $22,593.60. Insiders at CytomX Therapeutics own 6.6% of the company. Learn More about insider trades at CytomX Therapeutics.
Information on this page was last updated on 3/18/2025.

Lloyd A. Rowland Insider Trading History at CytomX Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/18/2025	Sell	10,203	$0.60	$6,121.80	120,594
3/19/2024	Sell	5,268	$2.09	$11,010.12	117,728
9/22/2023	Sell	5,486	$1.30	$7,131.80	80,609
3/16/2023	Sell	2,037	$1.98	$4,033.26	71,095
7/20/2022	Sell	5,602	$1.42	$7,954.84	43,689
3/4/2019	Buy	9,000	$10.33	$92,970.00	9,979

Lloyd A. Rowland Buying and Selling Activity at CytomX Therapeutics

CytomX Therapeutics Company Overview

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Today's Range

Now: $5.44

$5.44

$5.74

50 Day Range

MA: $4.97

$3.88

$6.09

2 Week Range

Now: $5.44

$0.40

$6.35

Volume

1,890,436 shs

Average Volume

3,280,351 shs

Market Capitalization

$921.73 million

P/E Ratio

13.60

Dividend Yield

N/A

Beta

2.44